Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA 02115, USA.
Curr Opin Immunol. 2023 Aug;83:102339. doi: 10.1016/j.coi.2023.102339. Epub 2023 May 26.
After two decades of the study of lipid antigens that activate CD1-restricted T cells, new studies show how autoreactive αβ T-cell receptors (TCRs) can directly recognize the outer surface of CD1 proteins in ways that are lipid-agnostic. Most recently, this lipid agnosticism has turned to negativity, with the discovery of natural CD1 ligands that dominantly negatively block autoreactive αβ TCR binding to CD1a and CD1d. This review highlights the basic differences between positive and negative regulation of cellular systems. We outline strategies to discover lipid inhibitors of CD1-reactive T cells, whose roles in vivo are becoming clear, especially in CD1-mediated skin disease.
经过二十年对激活 CD1 限制性 T 细胞的脂质抗原的研究,新的研究表明自身反应性的 αβ T 细胞受体 (TCR) 如何以脂质无关的方式直接识别 CD1 蛋白的外表面。最近,这种脂质无关性转向了负性,发现了天然的 CD1 配体,这些配体主要通过阴性阻断自身反应性的 αβ TCR 与 CD1a 和 CD1d 的结合。这篇综述强调了细胞系统正性和负性调节之间的基本差异。我们概述了发现 CD1 反应性 T 细胞的脂质抑制剂的策略,其在体内的作用越来越明显,尤其是在 CD1 介导的皮肤疾病中。